Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study

BACKGROUND: Although trastuzumab (T) represents the standard of care for the adjuvant treatment of HER2‐positive early‐stage breast cancer, contrasting results are available about the cardiac toxicity associated to its use. We conducted a multiregional population‐based cohort investigation aimed to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Franchi, Matteo, Trama, Annalisa, Merlo, Ivan, Minicozzi, Pamela, Tarantini, Luigi, Garau, Donatella, Kirchmayer, Ursula, Di Martino, Mirko, Romero, Marilena, De Carlo, Ilenia, Scondotto, Salvatore, Apolone, Giovanni, Corrao, Giovanni
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2020
Konular:
Breast Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543336/
https://ncbi.nlm.nih.gov/pubmed/32770690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0216
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller